November 2020 at a glance: focus on comorbidities and medical treatment

The role of glycaemic control in patients with heart failure (HF) and concomitant diabetes is controversial. Insulin treatment is associated with poorer outcomes in these patients.1,2 McAlister et al.3 investigated the relationship between glycaemic control, i.e. glycated haemoglobin (HbA1c), and cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus and atherosclerosis from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Results showed a U-shaped association between baseline HbA1c and CV outcome, with the lowest risk when HbA1c was around 7%.3

[1]  F. Iellamo,et al.  Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study , 2020, European journal of heart failure.

[2]  P. Ponikowski,et al.  Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials , 2020, European journal of heart failure.

[3]  S. Solomon,et al.  Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan , 2020, European journal of heart failure.

[4]  Akshay S. Desai,et al.  Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF , 2020, European journal of heart failure.

[5]  Akshay S. Desai,et al.  Serum potassium in the PARADIGM‐HF trial , 2020, European journal of heart failure.

[6]  J. McMurray,et al.  Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF , 2020, European journal of heart failure.

[7]  R. Holman,et al.  Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial , 2020, European journal of heart failure.

[8]  T. Kitai,et al.  Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study , 2020, European journal of heart failure.

[9]  Akshay S. Desai,et al.  The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE , 2020, European journal of heart failure.

[10]  E. Giannitsis,et al.  Cardiac iron concentration in relation to systemic iron status and disease severity in non‐ischaemic heart failure with reduced ejection fraction , 2020, European journal of heart failure.

[11]  R. Doughty,et al.  Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N‐terminal pro‐B‐type natriuretic peptide and high‐sensitivity troponin T , 2020, European journal of heart failure.

[12]  P. Ponikowski,et al.  Heart Failure Association of the European Society of Cardiology position paper on frailty in patients with heart failure , 2019, European journal of heart failure.

[13]  S. Solomon,et al.  Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction , 2019, European journal of heart failure.

[14]  G. Filippatos,et al.  Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations , 2019, European journal of heart failure.

[15]  A. Banerjee,et al.  Risk factors for incident heart failure in age‐ and sex‐specific strata: a population‐based cohort using linked electronic health records , 2019, European journal of heart failure.

[16]  J. Regensteiner,et al.  Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN‐HF registry , 2018, European journal of heart failure.

[17]  Akshay S. Desai,et al.  The frailty syndrome and outcomes in the TOPCAT trial , 2018, European journal of heart failure.

[18]  D. Pennell,et al.  Sex‐ and age‐based differences in the natural history and outcome of dilated cardiomyopathy , 2018, European journal of heart failure.

[19]  L. Lund,et al.  Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists , 2018, European journal of heart failure.

[20]  E. Steyerberg,et al.  Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA‐HF study , 2018, European journal of heart failure.

[21]  B. Giepmans,et al.  Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function , 2018, European journal of heart failure.

[22]  P. Ponikowski,et al.  Potassium and the use of renin–angiotensin–aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT‐CHF , 2018, European journal of heart failure.

[23]  K. Dickstein,et al.  Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes , 2017, European journal of heart failure.

[24]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.